Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 206Colonic Neoplasms 89Rectal Neoplasms 88Stomach Neoplasms 57Pancreatic Neoplasms 49Neoplasms 42Esophageal Neoplasms 42Neoplasm Metastasis 39Unspecified Adult Solid Tumor, Protocol Specific 30Lung Neoplasms 28Glioblastoma 27Brain Neoplasms 26Carcinoma, Non-Small-Cell Lung 24Central Nervous System Neoplasms 23Glioma 22Small Cell Lung Carcinoma 21Neuroblastoma 20Astrocytoma 18Adenocarcinoma Of Esophagus 18Esophageal Squamous Cell Carcinoma 17Gliosarcoma 16Breast Neoplasms 15Rhabdomyosarcoma 13Oligodendroglioma 12Sarcoma 11Adenocarcinoma 10Medulloblastoma 9Carcinoma, Hepatocellular 9Sarcoma, Ewing 8Gastrointestinal Neoplasms 8

Interventions

sapanisertib 2tovorafenib 1serabelisib 1pevonedistat 1Paclitaxel 1MLN 8237 1Irinotecan 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Nonhematologic Malignancies × Irinotecan × Clear all
NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
81 enrolled 33 charts

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡